Vera Therapeutics (NASDAQ:VERA – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $125.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 197.13% from the company’s previous close.
A number of other brokerages also recently weighed in on VERA. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. TD Cowen boosted their target price on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Raymond James Financial restated a “strong-buy” rating and issued a $84.00 price target on shares of Vera Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.15.
Read Our Latest Report on Vera Therapeutics
Vera Therapeutics Stock Down 4.1%
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.56) by $0.04. During the same period in the prior year, the firm posted ($1.20) EPS. On average, equities analysts predict that Vera Therapeutics will post -6.37 EPS for the current fiscal year.
Insider Activity at Vera Therapeutics
In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Vera Therapeutics
Several hedge funds have recently made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after purchasing an additional 17,907 shares during the period. Jane Street Group LLC lifted its holdings in shares of Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after purchasing an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after buying an additional 262,805 shares during the period. Finally, Legal & General Group Plc grew its holdings in shares of Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after buying an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.
Vera Therapeutics Company Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
See Also
- Five stocks we like better than Vera Therapeutics
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
